Targeting cancer metastases with precise alpha-particle radiation therapy
Official title: Core 1: Animal Models, Pathology and Tissue
Funded at Johns Hopkins University · NIH-10931461 · Data updated 2026-11-12
This study is looking at a new type of treatment that uses targeted radiation to fight cancer spread while protecting healthy cells, and it's designed for patients who want more personalized and effective options for their cancer care.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $216,032 |
| NIH project number | 5P01CA272222-02 |
| Project ID | NIH-10931461 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with disseminated cancer metastases who may benefit from targeted radiation therapy.
✕Less likely to help
Patients with localized cancers or those who do not have metastases may not receive benefit from this research.
What this research studies
This research investigates a new therapy called alpha-particle-emitter radiopharmaceutical therapy (αRPT) that aims to deliver targeted radiation to cancer metastases while minimizing damage to healthy tissues. By using advanced imaging techniques, the therapy can be precisely tailored to each patient's unique cancer profile, potentially leading to better treatment outcomes. The research involves animal models and human tissue analyses to refine the therapy and understand how it affects DNA damage and repair mechanisms. The goal is to optimize treatment plans and reduce the need for extensive human trials.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less toxic treatment option for patients with metastatic cancer.
How similar studies have gone: Previous research has shown promising results with similar targeted radiation therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Gabrielson, Kathleen Louise — Johns Hopkins University
- Study coordinator: Gabrielson, Kathleen Louise
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.